Your browser doesn't support javascript.
Detection of SARS-CoV-2 antibodies is insufficient for the diagnosis of active or cured COVID-19.
Escribano, Pilar; Álvarez-Uría, Ana; Alonso, Roberto; Catalán, Pilar; Alcalá, Luis; Muñoz, Patricia; Guinea, Jesús.
  • Escribano P; Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Álvarez-Uría A; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Alonso R; Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Catalán P; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Alcalá L; Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Muñoz P; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Guinea J; Medicine Department, Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Sci Rep ; 10(1): 19893, 2020 11 16.
Article in English | MEDLINE | ID: covidwho-927819
ABSTRACT
We assessed the performance of Abbott's SARS-CoV-2 IgG assay and the PanbioTM COVID-19 IgG/IgM rapid test device for the diagnosis of either active or cured COVID-19. Three cohorts of patients were chosen. Cohort 1, patients (n = 65) who attended the emergency department on March 30, 2020 with clinical suspicion of active COVID-19 (n = 56 with proven/probable COVID-19). Cohort 2, hospital workers (n = 92) who had either been (n = 40) or not (n = 52) diagnosed with proven/probable COVID-19 and were asymptomatic at the time of the sampling. Cohort 3, patients (n = 38) cared at the hospital before the start of the COVID-19 pandemic. Detection of serum antibodies was done using Abbott´s SARS-CoV-2 IgG assay and the PanbioTM COVID-19 IgG/IgM device. Both methods showed 98% agreement for IgG detection. No antibodies were detected in the 38 samples from hospitalized pre-COVID subjects. The diagnostic performance of IgGs detected by Abbott´s SARS-CoV-2 assay in Cohorts 1/2 was sensitivity (60.7%/75%) and specificity (100%/84.6%). The diagnostic performance of IgM by PanbioTM COVID-19 in Cohorts 1/2 was sensitivity (16%/17.5%) and specificity (100%/98.1%). We show that IgG detection alone is insufficient for the diagnosis of active or cured COVID-19. IgM detection has a limited diagnostic value.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Reagent Kits, Diagnostic / COVID-19 Serological Testing / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Sci Rep Year: 2020 Document Type: Article Affiliation country: S41598-020-76914-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Reagent Kits, Diagnostic / COVID-19 Serological Testing / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Sci Rep Year: 2020 Document Type: Article Affiliation country: S41598-020-76914-5